Cargando…

Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo

Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wright, Laura E., Harhash, Ahmed A., Kozlow, Wende M., Waning, David L., Regan, Jenna N., She, Yun, John, Sutha K., Murthy, Sreemala, Niewolna, Maryla, Marks, Andrew R., Mohammad, Khalid S., Guise, Theresa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352410/
https://www.ncbi.nlm.nih.gov/pubmed/28039445
http://dx.doi.org/10.18632/oncotarget.14139
_version_ 1782514965709586432
author Wright, Laura E.
Harhash, Ahmed A.
Kozlow, Wende M.
Waning, David L.
Regan, Jenna N.
She, Yun
John, Sutha K.
Murthy, Sreemala
Niewolna, Maryla
Marks, Andrew R.
Mohammad, Khalid S.
Guise, Theresa A.
author_facet Wright, Laura E.
Harhash, Ahmed A.
Kozlow, Wende M.
Waning, David L.
Regan, Jenna N.
She, Yun
John, Sutha K.
Murthy, Sreemala
Niewolna, Maryla
Marks, Andrew R.
Mohammad, Khalid S.
Guise, Theresa A.
author_sort Wright, Laura E.
collection PubMed
description Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypothesized that AI-induced bone loss could increase breast cancer progression in bone and exacerbate muscle weakness associated with bone metastases. Female athymic nude mice underwent ovariectomy (OVX) or sham surgery and were treated with vehicle or AI (letrozole; Let). An OVX-Let group was then further treated with bisphosphonate (zoledronic acid; Zol). At week three, trabecular bone volume was measured and mice were inoculated with MDA-MB-231 cells into the cardiac ventricle and followed for progression of bone metastases. Five weeks after tumor cell inoculation, tumor-induced osteolytic lesion area was increased in OVX-Let mice and reduced in OVX-Let-Zol mice compared to sham-vehicle. Tumor burden in bone was increased in OVX-Let mice relative to sham-vehicle and OVX-Let-Zol mice. At the termination of the study, muscle-specific force of the extensor digitorum longus muscle was reduced in OVX-Let mice compared to sham-vehicle mice, however, the addition of Zol improved muscle function. In summary, AI treatment induced bone loss and skeletal muscle weakness, recapitulating effects observed in cancer patients. Prevention of AI-induced osteoclastic bone resorption using a bisphosphonate attenuated the development of breast cancer bone metastases and improved muscle function in mice. These findings highlight the bone microenvironment as a modulator of tumor growth locally and muscle function systemically.
format Online
Article
Text
id pubmed-5352410
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53524102017-04-14 Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo Wright, Laura E. Harhash, Ahmed A. Kozlow, Wende M. Waning, David L. Regan, Jenna N. She, Yun John, Sutha K. Murthy, Sreemala Niewolna, Maryla Marks, Andrew R. Mohammad, Khalid S. Guise, Theresa A. Oncotarget Research Paper Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypothesized that AI-induced bone loss could increase breast cancer progression in bone and exacerbate muscle weakness associated with bone metastases. Female athymic nude mice underwent ovariectomy (OVX) or sham surgery and were treated with vehicle or AI (letrozole; Let). An OVX-Let group was then further treated with bisphosphonate (zoledronic acid; Zol). At week three, trabecular bone volume was measured and mice were inoculated with MDA-MB-231 cells into the cardiac ventricle and followed for progression of bone metastases. Five weeks after tumor cell inoculation, tumor-induced osteolytic lesion area was increased in OVX-Let mice and reduced in OVX-Let-Zol mice compared to sham-vehicle. Tumor burden in bone was increased in OVX-Let mice relative to sham-vehicle and OVX-Let-Zol mice. At the termination of the study, muscle-specific force of the extensor digitorum longus muscle was reduced in OVX-Let mice compared to sham-vehicle mice, however, the addition of Zol improved muscle function. In summary, AI treatment induced bone loss and skeletal muscle weakness, recapitulating effects observed in cancer patients. Prevention of AI-induced osteoclastic bone resorption using a bisphosphonate attenuated the development of breast cancer bone metastases and improved muscle function in mice. These findings highlight the bone microenvironment as a modulator of tumor growth locally and muscle function systemically. Impact Journals LLC 2016-12-25 /pmc/articles/PMC5352410/ /pubmed/28039445 http://dx.doi.org/10.18632/oncotarget.14139 Text en Copyright: © 2017 Wright et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Wright, Laura E.
Harhash, Ahmed A.
Kozlow, Wende M.
Waning, David L.
Regan, Jenna N.
She, Yun
John, Sutha K.
Murthy, Sreemala
Niewolna, Maryla
Marks, Andrew R.
Mohammad, Khalid S.
Guise, Theresa A.
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
title Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
title_full Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
title_fullStr Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
title_full_unstemmed Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
title_short Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
title_sort aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352410/
https://www.ncbi.nlm.nih.gov/pubmed/28039445
http://dx.doi.org/10.18632/oncotarget.14139
work_keys_str_mv AT wrightlaurae aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT harhashahmeda aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT kozlowwendem aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT waningdavidl aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT reganjennan aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT sheyun aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT johnsuthak aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT murthysreemala aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT niewolnamaryla aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT marksandrewr aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT mohammadkhalids aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo
AT guisetheresaa aromataseinhibitorinducedbonelossincreasestheprogressionofestrogenreceptornegativebreastcancerinboneandexacerbatesmuscleweaknessinvivo